alexa Novel NK Cell-mediated Targeted Immunotherapy For Cancer
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

Global Cancer Conference & Medicare Summit
September 15-17, 2014 Hyderabad International Convention Centre, India

Porunelloor A Mathew
Keynote: J Cancer Sci Ther
DOI: 10.4172/1948-5956.S1.036
Abstract
This presentation will address recent findings in NK cell mediated targeted therapy for cancer. Identification and characterization of NK cell receptors lead to a better understanding of the molecular basis of Natural Killer cell recognition and activation by cancer cells. NK cell functions are regulated by a delicate balance between signaling through activating receptors and inhibitory receptors. The interactions of activating receptors 2B4 (CD244), CS1 (CD319, CRACC) and LLT1 and their ligands (CD48, CS1 and CD 161) in modulating NK cytolytic function against cancer cells will be addressed. LLT1 expressed on cancer cells inhibit NK cell cytolytic function by interacting with the NK cell inhibitory receptor, NKRP1A (CD161). Monoclonal antibodies against NK receptors or their ligands could be used in inducing activation signals or blocking inhibitory signals from cancer cells. Current use of anti-CS1 mAb (Elotuzumab or Huluc63) against multiple myeloma and future prospects of use of anti-LLT1 mAb against glioblastoma and prostate cancer will be discussed.
Biography
Porunelloor A Mathew received his PhD in Biochemistry in 1987 from University of Pune, India. He did Postdoctoral fellowships at University of Medicine and Dentistry of New Jersey and UT Southwestern Medical Center, Dallas in the area of regulation of gene expression. He is one of the pioneers who identified, cloned and characterized several receptors expressed on NK cells. He also identified two other novel receptors called LLT1 and CS1 (CD319) that play a role in killing of cancer cells by NK cells. He was awarded a US patent for ?Immuno activation of CS1 receptor in Natural Killer cells to inhibit tumor cell growth?. His research has opened new NK cell based targeted immunotherapy for cancer.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords